potassium citrate: clinical use

Prescribing considerations

• Confirm the intended indication and formulation: cystitis products and modified-release tablets have different licences, precautions and administration requirements.
• Cystitis preparations are symptomatic treatments, not substitutes for assessment or antimicrobial treatment when clinically indicated.
• Review renal function, cardiac history, potassium intake and medicines that raise serum potassium.
• Consider gastrointestinal disease, urinary obstruction, active urinary infection, liver impairment and excipients in the intended formulation.

Contraindications and cautions

• Renodyra is contraindicated in substantial renal impairment, hyperkalaemia, active or persistent urinary infection, significant urinary obstruction, adrenal insufficiency, uncontrolled diabetes, alkalosis, severe myocardial injury, active peptic ulcer, delayed gastric emptying and intestinal obstruction.
• Potassium Citrate Mixture is contraindicated in hyperkalaemia, renal dysfunction, ventricular arrhythmias and Addison's disease.
• Cystopurin lists no specific contraindication in its SmPC but requires caution with renal impairment or cardiac disease; hypersensitivity remains relevant.

Monitoring

• For long-term modified-release treatment, monitor serum electrolytes, creatinine and full blood count as specified in the product information.
• Monitor renal function and serum potassium more closely in mild-to-moderate renal impairment, following treatment changes or if kidney function declines.
• Use urinary pH and urinary citrate to assess biochemical response in stone disease.
• Stop and assess urgently if hyperkalaemia, significant gastrointestinal injury or obstruction is suspected.

Clinical pharmacology

Potassium citrate is absorbed from the upper gastrointestinal tract; citrate is largely metabolised to bicarbonate. It raises urinary pH and citrate, reducing calcium activity and the crystallisation tendency of calcium oxalate and uric acid.

Formulation and product differences

• Modified-release tablets are prescription-only and licensed for selected adult stone disorders and renal tubular acidosis. They must remain intact and contain a wax matrix that may appear in faeces.
• Granules for oral solution are licensed for short-term cystitis symptom relief and contain aspartame, which is relevant in phenylketonuria.
• The oral mixture is licensed for dysuria associated with mild urinary infections. It must be shaken and diluted and contains sucrose, sodium benzoate and a small amount of ethanol.

Modified-release tablet

Route: Oral

Strengths: 1080 mg

Oral solution

Route: Oral

Strengths: 3 g